Patent intelligence · US
US 9902703
Somatostatin modulators and uses thereof
Somatostatin modulators and uses thereof
Patent details — US 9902703
- Jurisdiction
- US
- Status
- granted
- Grant date
- Feb 27, 2018
- Expiration
- Feb 22, 2038
- Applicant
- CRINETICS PHARMACEUTICALS, INC.
- Claims
- 17
- CPC classes
- A61P, A61P5/02
Quick answer
US 9902703 (Somatostatin modulators and uses thereof) is held by CRINETICS PHARMACEUTICALS, INC.. Status: granted. Granted Feb 27, 2018. Expires Feb 22, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- CRINETICS PHARMACEUTICALS, INC.
- Grant date
- Expiration
- Claims
- 17
- CPC classes
- A61P, A61P5/02
More from CRINETICS PHARMACEUTICALS, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12280046
Melanocortin subtype-2 receptor (MC2R) antagonist for the treatment of disease
granted -
US 12208092
Compositions and methods for administering paltusotine to patients with hepatic impairment
granted -
US 12134610
Somatostatin subtype-2 receptor (SST2R) targeted therapeutics and uses thereof
granted -
US 11957674
Formulations of a somatostatin modulator
granted -
US 11834462
Somatostatin modulators and uses thereof
granted -
US 11773076
Crystalline forms of a somatostatin modulator
granted -
US 11608335
Somatostatin modulators and uses thereof
granted -
US 11566015
Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof
granted
Frequently asked questions
What is US patent 9902703?
US 9902703 (Somatostatin modulators and uses thereof) is held by CRINETICS PHARMACEUTICALS, INC.. Status: granted. Granted Feb 27, 2018. Expires Feb 22, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9902703?
CRINETICS PHARMACEUTICALS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 26 pharmaceutical patents for this assignee.
When does US 9902703 expire?
Our index shows an expiration date of Feb 22, 2038 (12 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.